Abstract: Monitoring resource allocation requests to computer resources shared between a plurality of computers includes detecting an allocation request by an application for a first set of the plurality of computer resources and assigning the application to a group, wherein each member of the group comprises a respective application having an associated allocation request for an associated set of the plurality of computer resources. Determining that the first set of the plurality of computer resources cannot be allocated by the application, and determining that the first application generates a function call instructing other members of the group, if any, to request allocation of their associated set of the plurality of computer resources results in incrementing a counter value corresponding to the group. A message is sent when the counter value exceeds a predetermined threshold.

Abstract: Managing computer resource allocation includes detecting, by one computer amongst a plurality of computers, generation of an allocation request, wherein the allocation request requests exclusive access, by the one computer, to a computer resource shared between the plurality of computers; determining a period of time that has elapsed since detection of the generation of the allocation request; determining that a delay has occurred when the period of time has exceeded a predetermined threshold; and then, transmitting, by the one computer, a delay message based on the delay to each of the plurality of computers.

Abstract: Disclosed is a program for validating a web cache independent of an origin server. A computer in between a client computer and the origin server computer receives a request for a resource and an entity tag (ETag) corresponding to the request. The computer forwards the request to the origin server and subsequently receives the resource. The computer generates an ETag for the received resource and compares the generated ETag to the ETag corresponding to the request. If the ETags match, the computer sends an indication toward the client computer that the resource has not been modified.

Abstract: The present invention is directed to benzazole compounds that inhibit ?-site amyloid precursor protein-cleaving enzyme (BACE) and that may be useful in the treatment or prevention of diseases in which BACE is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which BACE is involved.

Abstract: Disclosed is a program for validating a web cache independent of an origin server. A computer in between a client computer and the origin server computer receives a request for a resource and an entity tag (ETag) corresponding to the request. The computer forwards the request to the origin server and subsequently receives the resource. The computer generates an ETag for the received resource and compares the generated ETag to the ETag corresponding to the request. If the ETags match, the computer sends an indication toward the client computer that the resource has not been modified.

Abstract: A roof covering includes a roofing mat formed from fibers of a fiber material. The fibers are coated with a sizing. The roof covering also includes a coating material that coats the mat. The coating material is based on an organic material. The sizing includes a sulfur-containing material that bonds to the fiber material. The sulfur-containing material has sulfur groups that form cross-links with the organic material. In another embodiment, the coating material contains sulfur added to the organic material. The sizing includes a bonding material that bonds to the fiber material and that bonds to the sulfur. The sulfur forms cross-links with the organic material.

Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Abstract: A roof covering includes a roofing mat formed from fibers of a fiber material. The fibers are coated with a sizing. The roof covering also includes a coating material that coats the mat. The coating material is based on an organic material. The sizing includes a sulfur-containing material that bonds to the fiber material. The sulfur-containing material has sulfur groups that form cross-links with the organic material. In another embodiment, the coating material contains sulfur added to the organic material. The sizing includes a bonding material that bonds to the fiber material and that bonds to the sulfur. The sulfur forms cross-links with the organic material.

Abstract: A paving mat for use in a paved surface includes a fibrous mat in the form of a paving mat. The fibrous mat includes a fibrous matrix containing a mixture of polymer fibers, first mineral fibers having a first median length, and second mineral fibers having a second median length that is different from the first median length. In another embodiment, the paving mat includes a fibrous mat including a fibrous matrix which is bonded together by a binder. In one embodiment, the binder is a mixture of different binders. The fibrous matrix includes a mixture of mineral fibers in an amount within a range of from 61 wt % to 85 wt % and polymer fibers in an amount within a range of from 15 wt % to 39 wt %. The polymer fibers have a melting point greater than 320° F. (160° C.). The mat has a stiffness in the machine direction within a range of from 65 g-cm to 110 g-cm.

Abstract: A roof covering includes a roofing mat formed from fibers of a fiber material. The fibers are coated with a sizing. The roof covering also includes a coating material that coats the mat. The coating material is based on an organic material. The sizing includes a sulfur-containing material that bonds to the fiber material. The sulfur-containing material has sulfur groups that form cross-links with the organic material. In another embodiment, the coating material contains sulfur added to the organic material. The sizing includes a bonding material that bonds to the fiber material and that bonds to the sulfur. The sulfur forms cross-links with the organic material.

Abstract: A method of producing a roofing shingle coating asphalt from a non-coating grade asphalt feedstock includes the following steps. The non-coating grade asphalt feedstock is partially blown to lower its penetration to a first penetration that is within or close to a target penetration range of the coating asphalt, and to raise its softening point to a first softening point that is lower than a target softening point range of the coating asphalt. A wax is added to the partially blown non-coating grade asphalt to further raise its softening point to a second softening point that is within the target softening point range to produce the coating asphalt. The wax may also be added during the blowing process. Resulting roofing coating asphalt compositions may comprise a paving grade asphalt and a wax, and yet still has desirable penetration, softening point and viscosity.

Abstract: In a process of producing a roofing shingle coating asphalt from a low flashpoint asphalt feedstock, an asphalt feedstock which has a low flashpoint of from 490° F. (254° C.) to 540° F. (282° C.) is partially blown, and wax is added to the asphalt feedstock. The process produces a coating asphalt having a low melt viscosity of from 50 cps to 150 cps at 400° F. (204° C.), a softening point of from 190° F. (88° C.) to 235° F. (113° C.) and a penetration of at least 15 dmm at 77° F. (25° C.). In another embodiment, the process produces a roofing shingle coating asphalt having good weatherability from a poor weathering asphalt feedstock. In a further embodiment, the process produces roofing shingles including a filled coating containing a poor tear filler without sacrificing the tear strength of the shingles.

Abstract: A method of producing a roofing shingle coating asphalt from a non-coating grade asphalt feedstock includes the following steps. The non-coating grade asphalt feedstock is partially blown to lower its penetration to a first penetration that is within or close to a target penetration range of the coating asphalt, and to raise its softening point to a first softening point that is lower than a target softening point range of the coating asphalt. Then a wax is added to the partially blown non-coating grade asphalt to further raise its softening point to a second softening point that is within the target softening point range to produce the coating asphalt.

Abstract: A process of producing a roofing shingle coating asphalt from an asphalt feedstock includes the following steps. Wax and blowing catalyst are added to the asphalt feedstock. Then the asphalt feedstock is blown to produce the coating asphalt. The coating asphalt has a softening point within a range of from about 190° F. (88° C.) to about 235° F. (113° C.) and has a penetration of at least about 15 dmm at 77° F. (25° C.).

Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephrdpathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Abstract: Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.

Abstract: This invention provides certain compounds, methods of their preparation, pharmaceutical compositions comprising the compounds, and their use in treating human or animal disorders. The compounds of the invention are useful as modulators of the interaction between the receptor for advanced glycated end products (RAGE) and its ligands, such as advanced glycated end products (AGEs), S100/calgranulin/EN-RAGE, ?-amyloid and amphoterin, and for the management, treatment, control, or as an adjunct treatment for diseases in humans caused by RAGE. Such diseases or disease states include acute and chronic inflammation, the development of diabetic late complications such as increased vascular permeability, nephropathy, atherosclerosis, and retinopathy, the development of Alzheimer's disease, erectile dysfunction, and tumor invasion and metastasis.

Abstract: A roof covering includes a coated roofing mat comprising a roofing mat coated with an organic-based coating material. A reflective layer comprising a layer of an infrared reflective material covers an upper surface of the coated roofing mat. A weatherable layer comprising a layer of a weatherable material covers an upper surface of the reflective layer. The roof covering does not include roofing granules.

Abstract: Synthetic methods and intermediates useful in the preparation of lactone containing compounds such as discodermolide and compounds which mimic the chemical or biological activity of discodermolide are provided.